Form D · Biotechnology
Kezar Life Sciences, Inc.
South San Francisco, CA · CIK 0001645666
Offering snapshot reported Aug 3, 2017 · SEC filing
- Reported sold
- $50M Offering amount: $50M
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 26, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 3, 2017 | Initial | $49,999,985 | No comparison | 24 | SEC filing |
| Jun 22, 2015 | Initial | $28,369,122 | No comparison | 49 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-292025
Source: Form D, filed Aug 3, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Franklin Berger | Director |
| Gerald Chan | Director |
| Dr. Gerald Chan | Director |
| Bihua Chen | Director |
| John F Fowler | Director, Executive |
| Michael Kauffman | Director |
| Christopher J Kirk | Director, Executive |
| Jean Pierre Sommadossi | Director |
| Dr. Jean Pierre Sommadossi | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
300 Utah Avenue Suite 105
South San Francisco, CA, 94080
South San Francisco, CA, 94080